Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model

Published: Friday, October 11, 2013
Last Updated: Friday, October 11, 2013
Bookmark and Share
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.

Compugen Ltd. has announced that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

The study was performed as part of an ongoing collaboration with Stephen Miller, Professor of microbiology-immunology at Northwestern University Feinberg School of Medicine.

The study utilized non-obese laboratory mice that spontaneously develop autoimmune insulin dependent diabetes.

Administration of CGEN-15001 to the mice began at 10 weeks of age, prior to manifestation of any clinical symptoms of the disease, and was continued for a period of only 2 weeks.

The mice were then monitored for blood glucose levels for an additional 4 months after the last treatment.

Results of the study demonstrate that treatment with CGEN-15001 prevented development of diabetes throughout the 4 months of follow-up. Animals treated with CGEN-15001 maintained normal blood glucose levels compared with untreated animals that developed high blood glucose.

The sustained duration of response following a short-term treatment with CGEN-15001, also observed previously in other disease models of autoimmunity, suggests that CGEN-15001 turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, thereby arresting disease progression.

"We have already shown through various preclinical studies that CGEN-15001 has the potential to serve as an efficacious disease modifying therapy for multiple sclerosis and rheumatoid arthritis," said Anat Cohen-Dayag, Ph.D., Compugen’s President and CEO.

Cohen-Dayag continued, "The results being reported today show that this Fc fusion protein also has a remarkable effect in a well-accepted disease model of type I diabetes, a severe, life-long disease with no current cure. These findings highlight the potential of CGEN-15001 to treat multiple autoimmune conditions and the promise of developing new effective immune modulating therapeutic drug candidates based on Compugen’s discovery platforms."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Announces Discovery of Two Drug Target Candidates for mAb Cancer Therapy
Targets are expressed in multiple cancers and have a distinct mode of action inhibiting two key immune cell subsets.
Tuesday, March 05, 2013
Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy
Expression levels of CGEN-15022 demonstrated in various types of epithelial cancers with significant unmet clinical needs, including liver, colorectal, lung and ovarian cancer.
Friday, June 29, 2012
Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference
Presentation includes disclosure of CGEN-15022 and CGEN-15092 as target candidates for antibody based cancer immunotherapy.
Tuesday, February 28, 2012
Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Retinopathy
CGEN-25017, a peptide antagonist predicted using Compugen’s DAC blockers discovery platform, demonstrates significant anti-angiogenic activity.
Thursday, July 23, 2009
Compugen Announces Positive Therapeutic Effects of Relaxin Receptor in Pulmonary Fibrosis
Relaxin receptor is third GPCR for which Compugen peptide ligands have demonstrated proof of efficacy in animal models.
Tuesday, April 07, 2009
Compugen Announces Inhibition of Angiogenesis by Novel Peptide
CGEN-25017 peptide antagonist of the Angiopoietin/Tie-2 pathway was predicted using Compugen’s DAC blockers discovery platform.
Friday, April 03, 2009
Compugen Announces Organizational Changes and Restructuring
Three units formed to support recently announced development and commercialization plans.
Monday, December 05, 2005
Scientific News
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!